R
Rolf Lewensohn
Researcher at Karolinska University Hospital
Publications - 229
Citations - 7777
Rolf Lewensohn is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 42, co-authored 204 publications receiving 6996 citations. Previous affiliations of Rolf Lewensohn include Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
Pia Baumann,Jan Nyman,Morten Høyer,Berit Wennberg,Giovanna Gagliardi,Ingmar Lax,Ninni Drugge,Lars Ekberg,Signe Friesland,Karl-Axel Johansson,Jo-Åsmund Lund,Elisabeth Morhed,Kristina Nilsson,Nina Levin,Merete Paludan,Christer Sederholm,Anders Traberg,Lena Wittgren,Rolf Lewensohn +18 more
TL;DR: With a 3-year local tumor control rate higher than 90% with limited toxicity, SBRT emerges as state-of-the-art treatment for medically inoperable stage I NSCLC and may even challenge surgery in operable instances.
Journal ArticleDOI
Human papillomavirus (HPV) DNA in tonsillar cancer : Clinical correlates, risk of relapse, and survival
TL;DR: It is indicated that HPV status is a significantly favorable prognostic factor in tonsillar cancer and may be used as a marker in order to optimize the treatment of patients with this type of cancer.
Journal ArticleDOI
The role of radiotherapy in treatment of stage I non-small cell lung cancer
TL;DR: Dose escalation, in a setting with conformal RT using involved field or stereotactic RT, should be the focus of developmental therapeutic strategies with inoperable stage I NSCLC to improve local control and survival.
Journal ArticleDOI
SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC
Jan Nyman,Andreas Hallqvist,Jo-Åsmund Lund,Odd Terje Brustugun,Bengt Bergman,Per Bergström,Signe Friesland,Rolf Lewensohn,Erik Holmberg,Ingmar Lax +9 more
TL;DR: SBRT is convenient for patients and should be considered standard treatment for patients with inoperable stage I NSCLC and there was no difference in PFS and OS between SBRT and conventionally treated patients despite an imbalance of prognostic factors.
Journal ArticleDOI
Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries
Pia Baumann,Jan Nyman,Ingmar Lax,Signe Friesland,Morten Høyer,Suzanne Rehn Ericsson,Karl-Axel Johansson,Lars Ekberg,Elisabeth Morhed,Merete Paludan,Lena Wittgren,Henrik Blomgren,Rolf Lewensohn +12 more
TL;DR: SBRT for stage I NSCLC results in favourable local control not inferior to fractionated RT and with acceptable toxicity and a statistically significant benefit survival for the higher doses.